+33 1 76 70 47 90
/
creativ@creativ-ceutical.com
Home
Who We Are
About Us
Strategic Management Board
What we do
Value & Market Access
Payer Landscape
Pricing Research
Early Dialog
PRMA Strategy
Evidence Generation
Decision Sciences & Outcomes Research
Modeling
HTA submission
Data Analytics
Evidence Synthesis
Patient-Centered Research
Real World Evidence
Exclusive Customized Consulting
Biotech Strategic Consulting
Corporate Strategic Consulting
Expertise
Senior Management
Partnerships
Japan
Publications
News & Events
Careers
Contact
Home
Who We Are
About Us
Strategic Management Board
What we do
Value & Market Access
Payer Landscape
Pricing Research
Early Dialog
PRMA Strategy
Evidence Generation
Decision Sciences & Outcomes Research
Modeling
HTA submission
Data Analytics
Evidence Synthesis
Patient-Centered Research
Real World Evidence
Exclusive Customized Consulting
Biotech Strategic Consulting
Corporate Strategic Consulting
Expertise
Senior Management
Partnerships
Japan
Publications
News & Events
Careers
Contact
Reasons for Aripiprazole Discontinuation in Schizophrenia – A Retrospective
Home
Publications
Reasons for Aripiprazole Discontinuation in Schizophrenia – A Retrospective
Back Home
Reasons for Aripiprazole Discontinuation in Schizophrenia – A Retrospective
2014 J Neurol Neurophysiol
Millier, A. | Briquet, B. | Georges, N. | Murthy, V. | Toumi, M. |
Volume: 5, Issue: , Pages: 5,
aripiprazole, Schizophrenia, antipsychotic drug, Europe, Safety, France, Germany, Sweden, therapy,
https://www.doi.org/http://dx.doi.org/10.4172/2155-9562.1000226
The website uses cookies.
Learn More
Ok